Sitemap | Contact

  • Company
  • Research and Development
  • Partnering
  • Management Team
  • Board of Directors
  • Contact
  • News
  • News

    News

 

Latest news

  • 23 April 2013
    Viscogel new share issue fully subscribed (PDF)
  • 19 April 2013
    Viscogels nyemission fulltecknad (PDF)
  • 28 March 2013
    Viscogel plans to raise SEK 20 million in a new share issue (PDF)
  • 26 March 2013
    Viscogel genomför nyemission (PDF)
  • 25 March 2013
    Viscogel demonstrates Proof-of-Concept in a phase I/II clinical trial (PDF)
  • 25 March 2013
    Viscogel visar Proof-of-Concept i klinisk fas I/II studie (PDF)
  • 05 June 2012
    Viscogel presented at Småbolagsdagen 2012
  • 02 May 2012
    Viscogel initiates phase I/II clinical trial for its novel vaccine adjuvant (PDF)
  • 27 February 2012
    Viscogel AB reports positive results from safety studies (PDF)
  • 02 January 2012
    Results on ViscoGel® adjuvant published in Vaccine (PDF)
  • 02 December 2010
    VISCOGEL RECEIVES RESEARCH GRANT FROM THE EU FOR PROJECT IN THE VACCINE FIELD (PDF)
 

Viscogel AB - Gunnar Asplunds Allé 32, Hus D,  171 63 Solna, Sweden - info@viscogel.se

Research and Development - Viscosan & ViscoGel, medical chitosans for a new class of adjuvants and vaccine carriers.

Technologies - Research and Development - Applications - Background - Links - Sitemap